Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are crucial for non-small-cell lung cancer (NSCLC) treatment.
• While effective, EGFR-TKIs can cause serious adverse events, including interstitial lung disease (ILD), a rare but fatal complication.
• The exact mechanisms behind EGFR-TKI-induced ILD remain unclear, hindering effective prevention and treatment.

Purpose of the Study:

• To investigate the relationship between EGFR-TKIs and adverse events, with a focus on interstitial lung disease (ILD).
• To review current literature on the mechanisms of EGFR-TKI-induced lung injury and resistance.
• To discuss potential therapeutic strategies for managing EGFR-TKI-related lung injury and overcoming treatment resistance.

Main Methods:

• Literature review of preclinical and clinical studies on EGFR-TKI mechanisms and adverse events.
• Analysis of risk factors associated with EGFR-TKI-induced ILD.
• Exploration of potential mechanisms involving cytotoxic or immunotherapeutic agents in combination with EGFR-TKIs.

Main Results:

• EGFR-TKIs are associated with significant adverse events, including a high mortality rate from ILD.
• Factors like smoking history and pre-existing lung conditions may exacerbate EGFR-TKI-induced lung injury.
• Combined therapies involving EGFR-TKIs may contribute to lung injury through complex mechanisms.

Conclusions:

• Understanding the pathogenesis of EGFR-TKI-induced ILD is critical for patient safety.
• Further research into diagnostic and therapeutic advancements is needed to mitigate lung injury and improve outcomes in NSCLC patients treated with EGFR-TKIs.
• Exploring novel treatment combinations and supportive care strategies is essential for managing EGFR-TKI-related toxicities.